Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
XSPRAY Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr23.00 - kr90.61
Previous CloseN/A
Volume2.99K
Average Volume (3M)44.57K
Market Cap
kr2.01B
Enterprise Valuekr2.01B
Total Cash (Recent Filing)kr125.72M
Total Debt (Recent Filing)kr126.96M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding37,138,493
10 Day Avg. Volume38,793
30 Day Avg. Volume44,570
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)3.46
Price to Sales (P/S)0.00
P/FCF Ratio-7.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xspray Pharma AB News
PremiumCompany Announcements
Xspray Pharma Achieves Key Milestone with XS003 Bioequivalence
PremiumCompany Announcements
Xspray Pharma Achieves Key FDA Milestone for Dasynoc
PremiumCompany Announcements
FDA Sets PDUFA Date for Xspray Pharma’s Dasynoc® Application
PremiumCompany Announcements
Xspray Pharma AB AGM Resolutions and Strategic InitiativesOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr23.00 and its highest was kr90.61 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr2.01B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Aug 06, 2025 which is in 19 days.
How were Xspray Pharma AB’s earnings last quarter?
Currently, no data Available
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 37,138,493 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Technical Analysis
SynAct Pharma AB
―
Saniona AB
―
Xbrane Biopharma AB
―
IRLAB Therapeutics AB Class A
―
Cantargia AB
―